AIM is expected to report earnings to rise 100.00% to -11 cents per share on April 07
Q4'24
Est.
$-0.12
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.09
Q1'24
Est.
$-0.12
Q4'23
Missed
by $0.14
The last earnings report on November 19 showed earnings per share of -5 cents, beating the estimate of -8 cents. With 191.75K shares outstanding, the current market capitalization sits at 13.43M.
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders